Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
REVELUTION: +68.9 mm³ more coronary plaque at 12mo with leuprolide vs relugolix in men on ADT + pelvic RT · relugolix may spare the heart.
Single prostate signal today: in men on ≥6mo ADT with definitive pelvic RT, relugolix produced less coronary plaque progression than leuprolide (adjusted 68.9 mm³ difference, NCPV-driven), a mechanistic correlate for HERO's MACE benefit. Surrogate imaging endpoint, N=94, 12-mo f/u · hypothesis-generating for ADT-agent choice when RT mandates androgen suppression.
read the full digest →Studies · 76
- REVELUTIONAdjusted 12-mo coronary plaque volume rose 68.9 mm³ more with leuprolide vs relugolix in men on ADT with pelvic RT.
- KEYNOTE-689 vs NIVOPOSTOPTwo positive phase III IO trials in resectable LA-HNSCC: perioperative pembro (EFS+) vs postoperative nivo (3yr DFS ~63 vs 53%), both layered on surgery+adjuvant CRT.
- GEC-ESTRO APBI Patient Selection Guidelines (2026 update)2026 update expands APBI eligibility to pTis/T1-2 ≤30mm, pN0/pN1mi, all histologies; contraindicated for BRCA, age <40, TNBC, EIC+, or extensive LVI.
- EAU 2026: MDT/SBRT Intensification in Oligometastatic Prostate Cancer (Fonteyne)review: MDT/SBRT delays progression and defers systemic Tx in oligomet HSPC; ARTO is the first RCT hinting at an OS benefit.
- NRG Oncology/RTOG 0848OS HR 0.96 (90% CI 0.79-1.18), p=0.77; adding adjuvant chemoradiation to gemcitabine did not improve survival after resected pancreatic head adenoca.
- RAPCHEM (BOOG 2010-03)10-yr LRR 2.9% overall with response-adapted RT de-escalation post-NAC; low across all risk strata.
- NRG Oncology RTOG 053910-yr PFS 85.2%, 72.2%, 42.5% for low/intermediate/high-risk WHO grade 1-3 meningioma at median ~12yr f/u.
- FIRESTORMDose-escalated postop RT: 5-yr PFS 65.8% vs 38.8%, MVA HR 0.40 (0.24-0.69) in high-risk meningioma.
- PrTK03 (aglatimagene besadenovec + EBRT)DFS HR 0.70 (0.52–0.94), p=0.016 favoring aglatimagene + valacyclovir + EBRT vs placebo in intermediate/high-risk localized prostate cancer.
- AREST3-yr LRFS 89.2% vs 80.9%, HR 0.52 (p=0.02) favoring adj RT in pT1-2 pN0 OSCC with intermediate-risk features; DFS/OS NS.
- mRCAT-IIIpCR 61% vs 29% (p<0.0001) with node-sparing SCRT + CAPOX + tislelizumab vs conventional SCRT + CAPOX in pMMR LARC.
- Breast RT + Systemic Therapy Concurrency Review (Speers)T-DXd ILD 9.6% vs T-DM1 1.6% (DESTINY-Breast05); ASCO26 PK-guided concurrency framework for breast RT + systemic agents.